From my interpretation (and I may be wrong), they needed many more patients with severe COPD or Asthma in the trial. Although they had clear cut results from people with moderate problems, reducing the days impacted by the cold might not necessarily be enough of an incentive for them to justify Vap. As I said, I might have totally misinterpreted this message, but you should feel free to follow-up directly with Russ or Joe.
- Forums
- ASX - By Stock
- BTA
- sydney meeting ?
sydney meeting ?, page-16
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online